Atai Beckley N.V. (ATAI)
NASDAQ:ATAI
Want to see ATAI full AI Analyst Report?
ATAI Stock Chart & Stats
$4.03
-$0.11(-6.29%)
At close: 4:00 PM EST
$4.03
-$0.11(-6.29%)
Day’s Range― - ―
52-Week Range$2.00 - $6.75
Previous CloseN/A
Volume1.44M
Average Volume (3M)4.81M
Market Cap
$1.77B
Enterprise Value$1.63B
Total Cash (Recent Filing)$230.77M
Total Debt (Recent Filing)$2.00M
Price to Earnings (P/E)―
Beta1.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding368,166,700
10 Day Avg. Volume4,706,750
30 Day Avg. Volume4,811,811
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue466.37
Enterprise Value/Gross Profit568.57
Enterprise Value/Ebitda-12.81
Forecast
1Y Price Target
$14.90Price Target Upside269.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity CushionA very low debt-to-equity ratio and sizable equity base provide a durable financial cushion that supports continued clinical spending and partnership activity without immediate refinancing. This balance-sheet strength increases capital flexibility, reduces near-term default risk, and helps fund multi-stage trials or strategic investments while management pursues value-creating milestones.
High Gross MarginsExceptionally high gross margins indicate attractive unit economics for any future product or licensed IP. If clinical candidates are commercialized or out-licensed, those margins support scalable profitability because costs are dominated by R&D and fixed expenses. Over the medium term, favorable gross margins enhance long-term margin recovery potential once revenue scales.
Platform / Partnership Business ModelA platform model built on partnerships, licensing, and program-level investments diversifies development risk and creates multiple potential non-dilutive cash paths (upfronts, milestones, royalties, strategic exits). Structurally, this optionality can accelerate development funding, enable selective asset monetization, and align incentives with external collaborators over the coming months.
Bears Say
Minimal And Declining RevenueRevenue scale is minimal and has recently declined, reflecting lack of commercialized products and limited recurring cash inflows. Over a multi-month horizon this weak top-line constrains the company's ability to internally fund trials or absorb setbacks, increasing dependency on external financing and reducing the buffer to support long-duration R&D programs.
Sustained Negative Cash Flow / High BurnVery large negative operating and free cash flow indicate structural burn tied to clinical and development activities. Such persistent outflows will consume liquid resources and force financing events or asset monetization within months absent material non-operating receipts. This ongoing reliance on external funding raises dilution and execution risk for long-term development plans.
Deep And Worsening LossesExtremely negative net margins and negative returns on equity signal heavy operating losses that are widening versus prior periods. Persistent negative profitability undermines internal value creation, can weaken negotiating leverage with partners, and increases the probability of additional capital raises, making long-term viability contingent on successful clinical readouts or strategic exits.
Atai Beckley N.V. News
ATAI FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was $2.00 and its highest was $6.75 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is $1.77B.
When is Atai Beckley N.V.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Atai Beckley N.V.’s earnings last quarter?
Currently, no data Available
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on Atai Beckley N.V. dividends here
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 368,166,700 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in ATAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.90 (269.73% Upside)
$14.90 (269.73% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Atai Beckley N.V.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
ATAI Stock 12 Month Forecast
Average Price Target
$14.90
▲(269.73% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Ownership Overview
32.34% Insiders
3.47% Mutual Funds
10.43% Other Institutional Investors
47.54% Public Companies and Individual Investors